Clinical trial NCT01431105
Conditions: Kawasaki Disease
Keywords: Kawasaki disease
Sponsor: University of California, San Diego
Start date: 2012-07-01; Completion date: 2018-07-01
Enrollment: 34 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery abnormalities that could lead to complications later in life, including heart attack. Although investigators can identify children with KD that have these coronary artery abnormalities, there is no approved additional treatment to decrease coronary artery inflammation and arrest or prevent damage to the coronary arteries. Inflammation and damage to the arterial wall is central to these coronary artery abnormalities. Statins, a class of drugs that is known for lowering cholesterol, have also been shown to decrease inflammation in general as well as at the level of the vessel wall. Therefore, the investigators propose to study the safety of the drug atorvastatin in children with coronary artery abnormalities from KD.

Detailed description:

Arms: arm 1: Atorvastatin dose titration to maximum tolerated dose
Interventions: intervention 1: Atorvastatin
Intervention descriptions: intervention 1: Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)

Protocol documents:
Prot_SAP_000.pdf: 
 
 
 
Study Proposal & Statistical Analysis Plan 
 
 
 
 
Phase I/IIa Study of Pharmacokinetics and Safety of Atorvastatin in 
Children with Coronary Artery Abnormalities Secondary to Kawasaki 
Disease 
 
 
 
Investigators: 
 
Adriana H. Tremoulet, MD, MAS 
Jane C. Burns, MD 
 
 
May 20, 2016 
 
NCT# 01431105 
 
 


I. Study Overview  
 
OVERALL OBJECTIVE 
The goal of this study is to determine the safety, pharmacokinetics and activity of atorvastatin in 
children with acute Kawasaki disease (KD) and coronary artery abnormalities. The goal will be to find a 
treatment that could prevent or attenuate coronary artery damage in acute KD. 
 
HYPOTHESIS  
We postulate that atorvastatin will be safe in children ≥ 2 years old with acute KD.  
 
STUDY TYPE 
This is a Phase I/IIa dose escalation study  
 
STUDY POPULATION  
Children ≥2 years to 17 years with acute KD who have a Z-score ≥ 2.5 or aneurysm (≥ 1.5 x the 
adjacent segment) of one of the coronary arteries. 
 
STUDY DURATION 
 4 years  
 
PRIMARY OUTCOME  
Safety of atorvastatin in the study population. 
 
SECONDARY OUTCOMES  
1. Pharmacokinetics of atorvastatin  
2. Activity of atorvastatin 
a. Biomarkers and measures of inflammation 
b. Echocardiographic assessment of coronary artery abnormalities 
 
II. Background & Significance 
IIA. Significance: 
KD, the most common cause of acquired heart disease in children in Western developed countries and 
Asia, is a systemic vasculitis of unknown etiology. In the United States, there are 5-6,000 new cases 
each year [1]. However, without a specific diagnostic test, the true burden of disease is unknown. At 
Rady Children’s Hospital San Diego, we cared for over 90 new KD cases in 2010 and follow over 1,200 
families in our outpatient KD Clinic (350 outpatient visits/yr.), of whom 9% developed aneurysms and 
25% developed dilated coronary arteries. In Japan, the country of highest incidence (>215/100,000 
children < 5 yrs), there are more than 12,000 new cases each year and rates continue to rise [2]. KD 
causes both a myocarditis and a vasculitis that damages the coronary arteries and other medium-sized 
muscular arteries [3, 4]. The major sequelae of aneurysms include thrombosis, late coronary artery 
stenosis, myocardial ischemia, myocardial infarction, and death [5, 6]. Clearly, aneurysm prevention 
is a primary goal of treatment during the acute phase of the disease, which leads us to focus on 
treatment of patients with early signs of coronary artery abnormalities (CAAs) in this 
application. 
 
Intravenous immunoglobulin (IVIG) in combination with aspirin is the only approved therapy for KD and 
no clinical trials have focused on blocking the progression of coronary artery dilatation or aneurysm 
formation in the subset of KD patients who develop this complication. The major acute risk of aneurysm 
formation is thrombosis, which can be prevented with systemic anti-coagulation with warfarin or 
enoxaparin in addition to antiplatelet therapy with aspirin or clopidogrel in patients with large aneurysms 


(>6 mm). However, there is no recommended therapy to halt the progression of arterial wall destruction 
and prevent aneurysm formation. In KD, CD8+ T-cells infiltrate the arterial wall and data from the 
Franco lab suggest that T-cell regulation is a key factor in reducing the acute inflammation[7, 8] The 
proposed studies will determine if atorvastatin is safe to use in young children and has 
demonstrable anti-inflammatory activity at a well-tolerated dose so that future studies can 
address the efficacy of atorvastatin in attenuating vascular wall damage and preventing 
aneurysms in KD patients. 
 
IIB. Importance of the problem 
Once aneurysms have formed, there is no way to turn back the biologic clock and undo them. The 
transmural inflammation destroys the normal architecture and even in children who remodel the 
aneurysm to form a more normal lumen, the vessel is never functionally normal again. The remodeled 
segment cannot dilate normally during increased myocardial oxygen demand and thus serves as a 
functional stenosis. It has been estimated that there are currently over 24,000 young adults in the 
United States with a history of KD, including over 8,000 with a history of coronary artery abnormalities. 
Without a new therapeutic approach this number is expected to grow by 1,400 individuals each year [6]. 
A recent study found that over 5% of all young adults (<40 years) evaluated by cardiac catheterization 
for suspected myocardial ischemia have aneurysms compatible with antecedent KD[9]. 
 
IIC. Validity of the approach 
A Phase I/IIa trial will generate sufficient data to determine if a full-scale Phase III trial is warranted. The 
trial will also establish if the anti-inflammatory effects of statins can be measured in children with an 
acute vasculitis. 
 
IID. Critical barriers to improving care 
Barriers to improving treatment for children with KD include the lack of a validated predictive score to 
identify those children at highest risk of aneurysm formation and lack of a therapeutic intervention that 
can prevent progression of CAAs once they have been detected. 
 
 
IIE. Potential to effect change in clinical practice 
The current clinical practice is to give every patient the same standard therapy (IVIG 2g/kg with aspirin 
80-100mg/kg) and to monitor for CAA. The mechanism of action of this immunomodulatory therapy 
remains unknown, but is being addressed by other research by the PI in collaboration with Dr. Franco 
(RO1 HL103536 and RO1 FD003514). In the unfortunate child who carries the genetic risk for CAA, no 
intervention to modify vessel wall inflammation is currently recommended [10].  
 
In a recent article entitled “Mining for therapeutic gold”, Director of the NIH, Dr. Francis Collins, stated 
that “drug repurposing” should be a strategy “to translate research into clinically useful products” [11]  . 
Our goal is to translate our findings on the role of matrix metalloproteinases (MMPs), T-cells, and 
myofibroblasts in KD aneurysm formation and “repurpose” the drug atorvastatin to test the hypothesis 
that the pleiotropic anti-inflammatory properties of this drug will prevent or attenuate coronary artery 
aneurysms in children with KD.  
 
IV. Specfic Aims 
Specific Aim 1 will test the hypothesis that a 6-week course of atorvastatin will be safe and well-
tolerated in children with KD and early CAAs.  
The safety of atorvastatin will be assessed. A dose escalation design will be used to find a dose in 
subjects that is tolerated with limited side effects. 
. 
 


V. Human subjects 
VA. Inclusion criteria: 
1. Age ≥ 2 years to 17 years old 
2. Meets clinical criteria for KD according to AHA guidelines (Table 2): Fever (T≥38oC or 100.4oC 
by oral or rectal route; if measured by a non-core route (i.e. Axillary, ear, temporal artery), then 
add 0.5 oC to temperature; by history acceptable)  ≥ 3 days and ≥ 2 clinical criteria with 
LAD/RCA z-score ≥ 2.5 or an aneurysm (≥ 1.5 x the adjacent segment) of one of the coronary 
arteries 
3. Patient presents within the first 20 days after fever onset  
4. Parent or legal guardian able and willing to provide informed consent and subject willing and 
able to provide assent when appropriate. 
5. Post-menarchal females: Negative pregnancy test at screening and willing to use two forms of 
contraception during the study 
6. Males engaging in sexual activity that could lead to pregnancy must use a condom. 
 
VB. Exclusion Criteria: 
1. Use of a statin, fibrate, or niacin within the 3 months prior to enrollment 
2. Have any chronic disease, except asthma, atopic dermatitis, autism or controlled seizure 
disorder  
3. Screening creatine phosphokinase (CK) ≥ 3x upper limit of normal for age 
4. Patient taking a CYP3A4 inhibitor (i.e. cyclosporine, clarithromycin or doxycycline) in the last 7 
days 
5. Patient has a history of allergy to atorvastatin or its derivatives 
 
VC. Data Collection: The following data will be recorded for all patients: 
1. Demographic data:  
• 
Patient's age at KD onset, sex, self-reported ethnicity of each biologic parent  
 
 
 
2. Clinical data:  
• 
Physical findings confirming the KD case definition (Table 2)[10] 
• 
Illness day at study entry 
• 
Response to IVIG (IVIG-resistance will be defined as persistent or recrudescent fever (T≥38.0˚C 
rectally) ≥36 h and < 7d following the end of the IVIG infusion (2g/kg)[14].) - 
• 
Name, dose and indication of concomitant medications taken from enrollment until study 
completed 
• 
Complete blood count, C-reactive protein (CRP), high sensitivity CRP (hsCRP), erythrocyte 
sedimentation (ESR), aspartate aminotransferase (AST), ALT, and GGT at baseline, 2 weeks 
and 6 weeks 
• 
CK and fasting lipid panel at baseline (after enrollment), 2 weeks and 6 weeks  
 
VI. Statistical analyses 
Incidence rates of adverse events and the proportion of subjects prematurely withdrawn from the study 
due to adverse events was compiled.  For continuous variables, the Kruskal Wallis Test was performed 
to compare the four dose levels. For categorical variables, Fisher’s Exact Test was performed.  
Statistical analyses were performed using the statistical software R (version 3.4.4) (http://www.r-
project.org). Analyses were performed following the intent-to-treat principle.  No adjustments for 
multiple comparisons were made for secondary analyses, and a p-value of 0.05 was considered 
statistically significant. 
 


 
VII. Literature Cited 
1. 
Kaneko, K., et al., Prediction of the Risk of Coronary Arterial Lesions in Kawasaki Disease by 
Brain Natriuretic Peptide. Pediatr Cardiol. 
2. 
Nakamura, Y., et al., Epidemiologic Features of Kawasaki Disease in Japan: Results of the 
2007-2008 Nationwide Survey. J Epidemiol, 2010. 
3. 
Yonesaka, S., et al., Endomyocardial biopsy in children with Kawasaki disease. Acta Paediatr 
Jpn, 1989. 31(6): p. 706-11. 
4. 
Yutani, C., et al., Histopathological study on right endomyocardial biopsy of Kawasaki disease. 
Br Heart J, 1980. 43(5): p. 589-92. 
5. 
Kato, H., et al., Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study 
of 594 patients. Circulation, 1996. 94(6): p. 1379-85. 
6. 
Gordon, J.B., A.M. Kahn, and J.C. Burns, When children with kawasaki disease grow up 
myocardial and vascular complications in adulthood. J Am Coll Cardiol, 2009. 54(21): p. 1911-
20. 
7. 
Franco, A., et al., Memory T-cells and characterization of peripheral T-cell clones in acute 
Kawasaki disease. Autoimmunity, 2010. 43(4): p. 317-24. 
8. 
Franco, A., et al., Endoplasmic reticulum stress drives a regulatory phenotype in human T-cell 
clones. Cell Immunol, 2010. 266(1): p. 1-6. 
9. 
Daniels, L.B., Tjajadi, MS, Walford, HH, Fernandez S, Trofimenko V, Fick DB, Phan, HAL, Linz 
PE, Nayak, K, Kahn AM, Burns, JC, Gordon JB., Prevalence of Kawasaki Disease in Young 
Adults with Suspected Myocardial Ischemia. Submitted. 
10. 
Newburger, J.W., et al., Diagnosis, treatment, and long-term management of Kawasaki disease: 
a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and 
Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart 
Association. Circulation, 2004. 110(17): p. 2747-71. 
11. 
Collins, F.S., Mining for therapeutic gold. Nature reviews. Drug discovery, 2011. 10(6): p. 397. 
12. 
Sato, Y.Z., et al., Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol, 2011. 
13. 
Tremoulet, A.H., et al., Evolution of Laboratory Values in Patients With Kawasaki Disease. 
Pediatr Infect Dis J, 2011. 
14. 
Tremoulet, A.H., et al., Resistance to intravenous immunoglobulin in children with Kawasaki 
disease. J Pediatr, 2008. 153(1): p. 117-21. 
15. 
Manlhiot, C., et al., Improved Classification of Coronary Artery Abnormalities Based Only on 
Coronary Artery z-Scores After Kawasaki Disease. Pediatr Cardiol, 2009. 
16. 
Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease 
(JCS 2008)--digest version. Circ J. 74(9): p. 1989-2020. 
17. 
Printz, B.F., et al., Noncoronary cardiac abnormalities are associated with coronary artery 
dilation and with laboratory inflammatory markers in acute kawasaki disease. J Am Coll Cardiol. 
57(1): p. 86-92. 
18. 
Kato, T., et al., Coronary arterial ectasia in a 2-year-old boy showing two symptoms of Kawasaki 
disease without manifesting fever. Rheumatol Int. 
19. 
Ravekes, W.J., et al., Aortic root dilation in Kawasaki disease. Am J Cardiol, 2001. 87(7): p. 
919-22. 
20. 
Chaudhuri, K., et al., Polymorphism in the promoter of the CCL5 gene (CCL5G-403A) in a 
cohort of North Indian children with Kawasaki disease. A preliminary study. Clin Exp Rheumatol.